种植体固位覆盖义齿对2型糖尿病与非糖尿病无牙颌患者的影响:前瞻性队列研究中的满意度与生活质量
这项单中心前瞻性队列研究纳入165名无牙颌成人(HbA1c<12%),比较健康者、血糖控制良好(HbA1c<8.1%)和控制不佳(HbA1c≥8.1%)的2型糖尿病患者在下颌2枚种植体覆盖义齿修复后12个月内的口腔健康相关生活质量(OHRQoL)和满意度。结果显示两个糖尿病组在6个月和12个月时的OHRQoL改善程度与非糖尿病对照组相同,满意度组间无差异,HbA1c未受时间或分组影响。
要点
- 两个糖尿病组在6个月和12个月时的OHRQoL改善程度与非糖尿病对照组相同。
- 满意度组间无差异,6个月和12个月时的增加相似。
- HbA1c未受时间或分组影响。
核心结论
- 种植体治疗为2型糖尿病患者的下颌2枚种植体覆盖义齿带来了显著的患者感知获益改善,与健康无牙颌个体相似。
- 这些获益延伸至血糖控制不佳的个体。
- 添加2枚种植体支持的下颌覆盖义齿在插入后12个月内未影响血糖状态。
研究设计与样本
- 单中心前瞻性队列研究,招募165名无牙颌成人(HbA1c<12%)接受下颌前部2枚骨内种植体以支持下颌覆盖义齿。
- 参与者按是否患2型糖尿病入组,2型糖尿病参与者按HbA1c分为控制良好(<8.1%)和控制不佳(≥8.1%)组。
- 在种植治疗前以及覆盖义齿(Locator附着体)插入后6个月和12个月时,参与者回答OHIP-20(OHRQoL)和McGill义齿满意度问卷,并在相同时间点测量HbA1c。
- 使用广义估计方程验证分组和时间效应(α=0.025)。
主要发现
- 12个月时,137名参与者提供了回答。
- 两个糖尿病组在6个月和12个月时的OHRQoL改善程度与非糖尿病对照组相同。
- 患者满意度显示相似改善,组间无差异,6个月和12个月时增加相似。
- HbA1c未受时间或分组影响。
关键数值与推荐
- 2型糖尿病控制良好组HbA1c<8.1%,控制不佳组HbA1c≥8.1%。
- OHIP-20用于评估OHRQoL,McGill义齿满意度问卷用于评估满意度。
- 广义估计方程检验α=0.025。
临床怎么用
- 种植体治疗可能为2型糖尿病患者提供重要的生活质量获益,独立于血糖状态。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the benefits of implant therapy for patients with diabetes, we compared (i) healthy, (ii) well controlled T2DM and (iii) poorly controlled T2DM patients, in terms of oral health-related quality of life (OHRQoL) and satisfaction with mandibular 2-implant overdentures over 12 months following restoration. MATERIALS AND METHODS: This single-center, prospective, cohort study recruited 165 edentulous adults (HbA1c<12%) to receive two endosseous implants in the anterior mandible to support mandibular overdentures. Participants were enrolled as having T2DM or not, with T2DM participants divided according to HbA1c into well-controlled (<8.1%) and poorly controlled (≥ 8.1%) groups. Participants provided responses to the OHIP-20 (OHRQoL) and the McGill Denture Satisfaction Questionnaire, before implant therapy and 6 and 12 months after overdenture insertion using Locator attachments. HbA1c was measured at the same time points. The effect of groups and time was verified using generalized estimating equations (α=0.025). RESULTS: At 12 months, 137 participants provided responses. The two diabetes groups showed improvements in OHRQoL to the same extent as the non-diabetic control group at both 6 and 12 months. Patient satisfaction showed similar improvements with no between-group differences and similar increases identified at 6 and 12 months. HbA1c was not affected by time or groups. CONCLUSIONS: Dental implant therapy provided significant improvements in patient-perceived benefits of mandibular two-implant overdentures for T2DM individuals, which are similar to those found for healthy edentulous individuals. Importantly, those benefits extend to those individuals with poorly controlled glycaemia. The addition of 2-implant supported mandibular overdentures did not affect glycaemic status over 12 months following insertion. CLINICAL SIGNIFICANCE: As risks for implant therapy relative to glycaemic status are better understood, this study documents that implant therapy may offer important benefits in QoL for T2DM patients independent of glycaemic status.
引用
- Herrero F, de Souza RF, Feine JS, et al. The impact of implant-retained overdentures on type-2 diabetic and non-diabetic edentulous patients: Satisfaction and quality of life in a prospective cohort study. J Dent. 2022. PMID: 36351489. doi:10.1016/j.jdent.2022.104357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。